AS;Hépatotoxicité des médicaments antituberculeux : Implications pratiques pour la surveillance

Gastroenterologie Clinique et Biologique

Volumn 22, Issue 2 BIS, 1998, Pages 117-120

  Durand, François ^a   Bernuau, Jacques ^b   Pessayre, Dominique ^b  

^a Sen ice d'Hépatologie et 1NSERM U24 ^*

^b BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

CHEMICALLY INDUCED DISORDER; HUMAN; LIVER DISEASE; REVIEW;

ANTITUBERCULAR AGENTS; HUMANS; LIVER DISEASES;

EID: 18544397720     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antitubcrculous treatment includina isoniazid. Hepatoloay 1995; 21:929-32.
2. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;146:1623-33.
3. Gulliford M, McKay AD, Prowse K. Cholestatic jaundice caused by ethambutol. Br Med J 1986;292:866.
4. Black M, Mitchell JR, Zimmerman HJ. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975;69:289-302.
5. Mitchell JR, Zimmerman HJ, Ishak KJ, Thorgeirsson UP, Timbrell JA, Snodgrass \VA, et al. Isoniazid liver injury: clinical spectrum, pathology and probable pathogenesis. Ann Intern Med 1976;84: 181-92.
6. Pessayre D, Bentata M, Degott C, Noucl O, Miguct JP, Rueff B, et al. Isoniazid rifampicin induced fulminant hepatitis: a possible consequence of enhancement of hepatotoxicity by enzyme induction. Gastroenterology 1977:72:284-9.
7. Pareil GC. Drug-induced liver disease. Edinburgh: Churchill Livingstone, 1994.
8. Danan G, Pessayre D, Larrey D, Benhamou JP. Pyrazinamide fulminant hepatitis. An old hepatotoxin strikes aaain. Lancet 1981; 2:1056.
9. Cross FS, Long MW, Banner AS, Snider DE. Rifampicin-isoniazid therapy in alcoholic and nonalcoholic tuberculous patients in a US health service cooperative therapy trial. Am Rev Resp Dis 1980;122:349-53.
10. Brande P, Steenbergen W, Vervoort G, Demedts M. Aging and hepatotoxicity of isoniazid and rifampicin for pulmonary tuberculosis. Am J Respir Crit Care Med 1995:152:1705-8.
11. Nolan CM, Sandblom RE, Thummel KE, Slattery JT, Nelson SD. . Hepatotoxicity asssociated with acetaminophen usage in patients receivinc multiple drua therapy for tuberculosis. Chest 1994; 105:408-11.
12. Wu JC, Lee SD, Yeh PF Chan CY, Wang YJ, Huang YS, et al. Isoniazid-rifampicin induced hepatitis in hepatitis B carriers. Gastroenterology 1990;98:502-4.
13. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antituberculous treatments. Rationale for monitoring liver status. Drug Saf 1996;15:394-405.
14. Altman C, Biour M, Grange J. Toxicité hépatique des antitubercu-leux. Rôle des différents médicaments. 199 observations. Presse Med 1993;22:1212-6.
15. Snider DE, Caras GJ. Isoniazid associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992;145:494-7.
16. Bernuau J, Durand F. L'insuffisance hépatique fulminante et subfulminante, urgence de prévention. Gastroenterol Clin Biol 1997:21:387-90.